BioSpace News Archive

Bio-Thera Solutions Announces FDA Accepts Biologics License Application for BAT1706, a Proposed Biosimilar to Avastin ®

Marius Pharmaceuticals, a specialty pharmaceutical company focusing on treating conditions that are primarily associated with testosterone deficiency, today announced that it has appointed Himanshu H. Shah and Shalin Shah as co-CEOs to drive the next phase of growth as the company looks to a potential launch of KYZATREX® in Q4 2021 and further the development of Marius’ deep clinical pipeline.

Innovative Practice Delivers VIP Experience for Patients Needing Joint Care and Replacement Through Private Outpatient Surgery Center and Boutique Recovery Suites

OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) today announced a new collaboration agreement with MAbSilico, a deep technology innovative TechBio located in Tours, France, to use artificial intelligence (AI)-based software for therapeutic monoclonal antibody drug development.

AVRA Medical Robotics, Inc. (“AVRA” or “the Company”) (OTC: AVMR) today issued the following update:

Endogena Therapeutics Inc., which discovers and develops endogenous regenerative medicines, today announced that it has successfully completed a first round of Series A financing, which was capped at $8 million.

When the cold weather arrives, so does lowered humidity, making dry and itchy skin an uncomfortable but customary part of the winter season as the body naturally reacts to the abrupt temperature changes.

In the phase II CodeBreak 100 trial, sotorasib provided durable clinical benefit with a favorable safety profile in patients with pretreated non-small cell lung cancer and who harbor KRAS p.G12C mutations, validating CodeBreak 100’s phase I results, according to research presented at the International Association for the Study of Lung Cancer World Conference on Lung Cancer.

Amgen (NASDAQ: AMGN) today announced results from the Phase 2 cohort of the CodeBreaK 100 clinical study evaluating investigational sotorasib (AMG 510) in 126 patients with KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC)

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the prevention and treatment of infectious diseases and related illnesses, today announced its third quarter financial results for the quarter ended September 30, 2020.